Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
2PHARMA HOLDING from Gent, company number BE0644751377, closed financial year 2025 with a result of € -3,205 after tax. For that financial year 2PHARMA HOLDING recorded a gross margin of € -1,803 and equity of € 34,480. Compared with financial year 2024, the result moved from € -3,465 to € -3,205. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ 34,480
▼ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3,205
▲ 7 % less loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € -27,020.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,065
▲ 10% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -2,486 | € -3,421 | € -2,727 | € -1,803 | ▲ € 924 |
| Profit after taxes | € -3,922 | € -5,619 | € -3,465 | € -3,205 | ▲ € 260 |
| Equity | € 46,769 | € 41,150 | € 37,685 | € 34,480 | ▼ 9% |
| Total debts | € 1,867,582 | € 1,869,936 | € 1,867,793 | € 1,831,834 | ▼ 2% |
| Cash | € 48,033 | - | - | - | |
| Retained profit | € -14,731 | € -20,350 | € -23,815 | € -27,020 | ▼ € 3,205 |
| Balance sheet total | € 1,914,350 | € 1,911,085 | € 1,905,478 | € 1,866,314 | ▼ 2% |
Key figures of 2PHARMA HOLDING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to 2PHARMA HOLDING?
What happened at 2PHARMA HOLDING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Aquitania BV stepped down as director. NBB
- MD Consult BV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 3,205. Source: NBB ↗
- Aquitania BV became a director. NBB
- MD Consult BV became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 3,922 loss in 2022 to € 3,205 loss in 2025.
A new publication or filing at 2PHARMA HOLDING? We notify you, reason included.
Follow 2PHARMA HOLDINGDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Ceres Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
2PHARMA HOLDINGThe shares are held by Ceres Pharma (100%). It owns 100% of 2Pharma itself.
Directors
According to the 2025 annual accounts
Director · represented by Anja Imschoot
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium, DGPharma, Labophar, MD Pharma, GLOBIFER INTL, CREDOPHAR +1 more
since 2026 · until 2032
Managing director · represented by Mario Debel
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, MD Pharma, Azur Medical, AUGMENTED ANATOMY, GLOBIFER INTL, CREDOPHAR, 2PHARMA
since 2026 · until 2032
Shareholders
100%
Participations
100%
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
DGPharma same network
€ 94,120 gross margin · 2024
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Website info
Features
Security
Details
- Company number
- 0644.751.377
- VAT number
- BE 0644.751.377
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- 2PHARMA HOLDING
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 December 2015
- Peppol
- Active · Active since 1 Aug 2025
- Contact
- ceres-pharma.com